ERBB2 and breast carcinoma: When GW9662 is present, we found that the sensitivity of BT474 pyrotinib-resistant cell line to pyrotinib was significantly enhanced (Figure 7C), indicating that GW9662 can reverse the drug resistance of HER2-positive breast cancer cells and make them sensitive to the drug again.